Glycobiology Advance Access originally published online on May 1, 2008
Glycobiology 2008 18(7):559-565; doi:10.1093/glycob/cwn038
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Published by Oxford University Press 2008.
Adjuvant potential of archaeal synthetic glycolipid mimetics critically depends on the glyco head group structure
3 National Research Council of Canada, Institute for Biological Sciences, 100 Sussex Drive, Ottawa, Ontario K1A 0R6, Canada
1 To whom correspondence should be addressed: Tel: +1-613-998-7891; Fax: +1-613-952-9092; e-mail: dennis.sprott{at}nrc-cnrc.gc.ca
Received on February 28, 2008; revised on April 4, 2008; accepted on April 28, 2008
Subunit vaccines capable of providing protective immunity against the intracellular pathogens and cancers that kill millions of people annually require an adjuvant capable of directing a sufficiently potent cytotoxic T lymphocyte response to purified antigens, without toxicity issues. Archaeosome lipid vesicles, prepared from isoprenoid lipids extracted from archaea, are one such adjuvant in development. Here, the stability of an archaeal core lipid 2,3-di-O-phytanyl-sn-glycerol (archaeol) is used to advantage to synthesize a series of disaccharide archaeols and show that subtle variations in the carbohydrate head group alters the type and potency of immune responses mounted in a mammal. Critically, a glycosylarchaeol was required to elicit high cytotoxic CD8+ T cell activity, with highest responses to the antigen entrapped in archaeosomes containing disaccharides of glucose in β- or 
1–6 linkage (β-gentiobiose, β-isomaltose), or of β-lactose. This first study on synthetic archaeal lipid adjuvants reveals potential for this class of regulatory friendly, easily scalable, inexpensive, and potent glyco-adjuvant.
Key words: adjuvant / archaea / disaccharides / glycosylarchaeols / synthesis
2 Present address: Université de Montréal, Faculté de Médecine Vétérinaire, St. Hyacinthe, 3200 Sicotte, Québec J2S 7C6, Canada.